Soft Tissue Sarcoma
Research activity centers on high-risk soft tissue sarcoma of the extremity, with attention to aggressive localized tumors including undifferentiated pleomorphic sarcoma and dedifferentiated/pleomorphic liposarcoma.
- Extremity sarcoma
- Localized high-risk disease
- Tumors larger than 5 cm
- Grade 2 or 3 sarcoma
The sponsor’s funded research is directed toward surgical oncology settings where local control and disease recurrence are central clinical concerns.
Radiation Oncology
Clinical interest includes radiotherapy as a key component in the management of localized sarcoma, particularly in the preoperative setting.
- Neoadjuvant radiotherapy
- Local tumor control
- Pre-surgical treatment
This area reflects a focus on integrating radiation-based treatment into multimodal care for extremity sarcoma.
Immuno-Oncology
The sponsor also supports research involving pembrolizumab, highlighting interest in immune-based treatment strategies for sarcoma.
- Checkpoint inhibition
- Perioperative immunotherapy
- Adjuvant treatment
Its research portfolio includes combining immune therapy with local treatment approaches in patients with resectable disease.
Surgical Oncology
Funded studies involve surgical resection as part of curative-intent care for patients with localized extremity sarcoma.
- Resectable sarcoma
- Perioperative treatment planning
- Postoperative disease control
Research in this area is closely tied to treatment sequencing around surgery and recurrence prevention.
